About Us
Our mission is to empower people living with neuromuscular diseases to live longer, more independent lives.
Statement from the Muscular Dystrophy Association on Sarepta Therapeutics’ Safety Update on ELEVIDYS
New York, Tuesday, March 18, 2025 – The Muscular Dystrophy Association (MDA) is deeply saddened by the news of a reported fatal case of acute liver failure months following treatment with ELEVIDYS. Our thoughts are with the family and loved ones affected by this tragic loss.
As the largest convener and only umbrella organization focused on over 300 neuromuscular diseases, we continue our 75-year commitment to individuals and families affected by Duchenne muscular dystrophy.
We recognize the importance of ongoing research and innovation while prioritizing patient safety. MDA is closely monitoring developments related to this case and will continue to work with the scientific and medical communities to ensure that people living with Duchenne and their families have access to the latest, most accurate information. We encourage families to consult with their healthcare providers to make informed decisions about their treatment options. In addition, families and medical professionals may contact the MDA Resource Center and Gene Therapy Support Network here.
Read more from Sarepta Therapeutics here.
